

Home

August 24, 2017

Thomas A. Ban: Towards Education in the History of Neuropsychopharmacology

Part XII

Collated Documents

All entries on INHN's website, regardless of whether they are essays or vignettes, are open for comments which may or not be followed by an active exchange (replies, responses and even responses to responses).

The "collating" of each exchange begins with the posting of the first comment. It continues until the project becomes inactive and/or after a minimum of six months inactivity becomes terminated.

All terminated exchanges are converted into "collated documents" and posted. In the course of conversion, it is ascertained that each "collated document" is fully comprehensible.

Projects which are not followed by an active exchange may also be terminated after six months of posting and some of the terminated projects without an exchange are combined into one collated document and posted.

All INHN members are invited to make a "final comment" on each posted "collated document." These "final comments" will not be replied to individually, but in one "final reply" by the author of the essay/vignette.

For each project, the "final comments" and the "final reply" to these "final comments" will be posted. After posting the "final document" of the project that includes the "collated document," the "final comments" on the "collated document" and the "final reply" to the comments, the "final document" will remain accessible for readers in the INHN Collection of INHN's electronic archives.

As shown below, there are 20 "collated documents" to-date in the INHN Collection of INHN's electronic archives.

Burton Angrist: Studies of Amphetamine Psychosis:**Clinical and Biological Aspects****August 3, 2017****Thomas A. Ban: Conflict of Interest: Marketing vs. Education****November 3, 2016**

(Contributions by Thomas A. Ban, Barry Blackwell, Jose de Leon, Samuel Gershon, Donald F. Klein and Larry Stein)

Ernst Franzek's final comment comment

February 9, 2017

Edward Shorter's final comment

April 6, 2017

Thomas A. Ban's final reply

June 15, 2017

Final document

June 29, 2017

Thomas A. Ban: From Melancholia to Depression: A History of diagnosis and treatment.**August 17, 2017**

(Contributions by Thomas A. Ban and Hector Warnes)

Thomas A. Ban: RDoC in Historical Perspective. Redefining Mental**Illness by Tanya M. Luhrmann. Samuel Gershon's question****February 9, 2017****Thomas. A. Ban: The Wernicke – Kleist – Leonhard Tradition with****Special Reference to Mania, Melancholia and Manic-depressive Psychosis****November 24, 2016**

(Contributions by Barney Carroll, Jose de Leon, Samuel Gershon, Martin M. Katz, and Antonio Egidio Nardi)

Thomas A. Ban and Marcelo Cetkovich-Bakmas: Carl Wernicke's**Elementary Symptoms and Sejunction Hypothesis / Theory****December 1, 2016**

(Contributions by Thomas A. Ban, Marcelo Cetkovich-Bakmas)

and Hector Warnes)

Ernst Franzek's Final Comment

May 4, 2017

Barry Blackwell: Adumbration: A History Lecture

December 15, 2016

(Contributions by Barry Blackwell, Samuel Gershon, Donald F. Klein, Edward Shorter and Andre Barciela Veras)

Barry Blackwell: Joel Elkes An Integrative Life

December 22, 2016

(Contributions by Ross Baldessarini, Robert Belmaker, Barry Blackwell, William Bunney, Reid Finlayson, Samuel Gershon, Paul Grof, James Harris)

Barry Blackwell: Heinz Edgar Lehmann

December 29, 2016

(Contributions by Per Bech, Barry Blackwell, Paul Grof, Irwin J. Kopin, and Mary and Philip Seeman)

Barry Blackwell: Risk and Relevance to Lithium Usage

Unpublished letter to the Editor of JAMA

July 20, 2017

(Contributions by Barry Blackwell, Samuel Gershon and Gordon Johnson)

Barry Blackwell: The Lithium Controversy: A Historical Autopsy

April 6, 2017

(Contributions by Jules Angst, Thomas A. Ban, Barry Blackwell, Samuel Gershon, Paul Grof, Gordon Johnson, Martin Katz Malcolm Lader and Janusz Rybakowski)

Samuel Gershon's comment

July 20, 2017

Gregory de Moore's comment July 27, 2017

Hector Warnes' comment July 27, 2017

Barry Blackwell: Thudichum: Father of Neurochemistry July 13, 2017

(Contributions by Barry Blackwell and Edward Shorter)

**Paul Devenyi: Addictions are not Treatable Diseases & Treatment
of Addiction is not a Success Story November 17, 2016**

(Contributions by Paul Devenyi and Peter R. Martin.)

Martin M. Katz: Clinical Trials of Antidepressants.

How Changing the Model Can Uncover New Antidepressants March 23, 2017

(Contributions by Per Bech, Walter Brown, Martin Katz and
Malcolm Lader)

Walter Brown's final comment August 3, 2017

Martin M. Katz: Component-specific vs Diagnosis-specific Clinical Trial May 11, 2017

(Contributors: Martin M. Katz and Donald F. Klein)

**Martin M. Katz: Depression and Drugs. The Neurobehavioral
Structure of a Psychological Storm June 22, 2017**

(Contributions by Per Beech, Samuel Gershon, Martin Katz and
Donald Klein)

Martin M. Katz: Multivantaged vs Conventional Assessment Method June 29, 2017

(Contributions by Martin M. Katz and Donald F. Klein)

Martin M. Katz: Onset of Clinical Action of Antidepressants**May 11, 2017**

(Contributions by Martin M. Katz, Donald F. Klein, Carlos Morra, Les Morey and Elemer Szabadi)

Ildiko Miklya: The History of Sergilin(-) Deprenyl the First Selective Inhibitor of B-Type Monoamine Oxidase and the First Synthetic Catecholaminergic Enhancer Substance**July 27, 2017**

(Samuel Gershon, Ildiko Miklya and Ervin Varga)

Julio Moizeszowicz: Psychodynamic Psychopharmacology & Julio Moizeszowicz and Mirta Moizeszowicz: Psychopharmacology and Freudian Theory**December 8, 2016**

(Contributions by Julio Moizeszowicz, Carlos Morra and Hector Warnes)

August 24, 2017

August 24, 2017